Overview
- Q3 revenue rose 54% to $17.6 billion with adjusted EPS of $7.02, and full‑year revenue guidance increased to $63.0–$63.5 billion with adjusted EPS guided to $23.00–$23.70.
- Mounjaro generated about $6.52 billion and Zepbound about $3.57 billion in the quarter, with gains driven largely by higher volumes partially offset by lower realized prices.
- Year‑to‑date tirzepatide sales have eclipsed Merck’s Keytruda, making the franchise the world’s top‑selling medicine so far in 2025.
- Lilly moved to broaden access through a Walmart partnership offering in‑store pickup of discounted Zepbound vials for cash‑pay patients, while advancing oral candidate orforglipron and expanding manufacturing in Puerto Rico with a planned Texas facility.
- Competition intensified as Novo Nordisk launched a rival bid for Metsera and payers exerted formulary pressure earlier this year, even as investors pushed Lilly shares higher on the beat‑and‑raise quarter.